Spinraza European Label Updated to Reflect Long-term Benefits in Broad Range of SMA Patients
The European label for Spinraza (nusinersen) has been updated to include longer-term benefits seen in pre-symptomatic treatment of spinal muscular atrophy (SMA), as well as in patients with infantile- and later-onset forms of the disease. Overall, the results from four clinical trials show sustained lessening or…